GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Penumbra Inc (NYSE:PEN) » Definitions » Cyclically Adjusted Price-to-FCF

Penumbra (Penumbra) Cyclically Adjusted Price-to-FCF : (As of Apr. 27, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Penumbra Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Penumbra Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Penumbra's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Penumbra Cyclically Adjusted Price-to-FCF Chart

Penumbra Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Penumbra Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Penumbra's Cyclically Adjusted Price-to-FCF

For the Medical Devices subindustry, Penumbra's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Penumbra's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Penumbra's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Penumbra's Cyclically Adjusted Price-to-FCF falls into.



Penumbra Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Penumbra's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Penumbra's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.83/129.4194*129.4194
=0.830

Current CPI (Dec. 2023) = 129.4194.

Penumbra Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201312 0.000 98.326 0.000
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 -0.162 99.621 -0.210
201506 -0.249 100.684 -0.320
201509 -0.563 100.392 -0.726
201512 -0.302 99.792 -0.392
201603 -0.097 100.470 -0.125
201606 -0.261 101.688 -0.332
201609 0.070 101.861 0.089
201612 -0.500 101.863 -0.635
201703 -0.032 102.862 -0.040
201706 -0.046 103.349 -0.058
201709 0.191 104.136 0.237
201712 -0.154 104.011 -0.192
201803 0.220 105.290 0.270
201806 -0.060 106.317 -0.073
201809 0.262 106.507 0.318
201812 0.106 105.998 0.129
201903 -0.125 107.251 -0.151
201906 -0.051 108.070 -0.061
201909 0.390 108.329 0.466
201912 -0.089 108.420 -0.106
202003 -0.441 108.902 -0.524
202006 -0.802 108.767 -0.954
202009 -0.213 109.815 -0.251
202012 -0.160 109.897 -0.188
202103 -0.489 111.754 -0.566
202106 -0.176 114.631 -0.199
202109 0.815 115.734 0.911
202112 -0.448 117.630 -0.493
202203 -0.245 121.301 -0.261
202206 -1.165 125.017 -1.206
202209 -0.508 125.227 -0.525
202212 -0.059 125.222 -0.061
202303 0.236 127.348 0.240
202306 0.325 128.729 0.327
202309 0.701 129.860 0.699
202312 0.830 129.419 0.830

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Penumbra  (NYSE:PEN) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Penumbra Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Penumbra's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Penumbra (Penumbra) Business Description

Traded in Other Exchanges
Address
One Penumbra Place, Alameda, CA, USA, 94502
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are primarily sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.
Executives
Harpreet Grewal director C/O VISTAPRINT USA, INCORPORATED, 100 HAYDEN AVE., LEXINGTON MA 02050
Surbhi Sarna director ONE PENUMBRA PLACE, ALAMEDA CA 94502
Johanna Roberts officer: EVP, Gen. Counsel & Secretary PENUMBRA, INC., ONE PENUMBRA PLACE, ALAMEDA CA 94502
Bridget O'rourke director ONE PENUMBRA PLACE, ALAMEDA CA 94502
Adam Elsesser director, officer: Chairman, CEO and President 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Don W. Kassing director 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Thomas Wilder director 2 MUSICK, IRVINE CA 92618
Arani Bose director, officer: Chief Innovator 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Lynn Rothman officer: EVP and Chief Business Officer 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
James Robert Pray officer: President, International 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Sridhar Kosaraju officer: CFO and Head of Strategy 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Maggie Yuen officer: Chief Financial Officer ONE PENUMBRA PLACE, ALAMEDA CA 94502
Lambert Shiu officer: Chief Accounting Officer ONE PENUMBRA PLACE, ALAMEDA CA 94502
Janet Leeds director ONE PENUMBRA PLACE, ALAMEDA CA 94502
Robert D. Evans officer: EVP, Gen. Counsel & Secretary ONE PENUMBRA PLACE, 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502